Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HBsAg nanobody 2nd generation
- Development stage
- Unknown
- Lead developer
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-HBsAg nanobody 2nd generation is a therapeutic single-domain antibody (VHH) designed to target the Hepatitis B surface antigen (HBsAg). Developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University, this agent is intended for the treatment of chronic hepatitis B. It functions by binding to HBsAg to neutralize the virus and facilitate the clearance of circulating surface antigens, which is a critical step toward achieving a functional cure. The "second-generation" designation typically refers to an optimized structure, such as a biparatopic or multivalent format (e.g., VHH-003), providing enhanced binding affinity and broader coverage of HBV genotypes compared to earlier monovalent versions. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in reducing HBsAg levels.
- Other names
- anti-HBsAg nanobodyVHH single-domain antibody (2nd gen)
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on anti-HBsAg nanobody 2nd generation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HBsAg nanobody 2nd generation.